Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation (Q96302550)
Jump to navigation
Jump to search
scientific article published on 11 June 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation |
scientific article published on 11 June 2020 |
Statements
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation (English)
F Heidel